Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia.

Deeg MA, Buse JB, Goldberg RB, Kendall DM, Zagar AJ, Jacober SJ, Khan MA, Perez AT, Tan MH; GLAI Study Investigators.

Diabetes Care. 2007 Oct;30(10):2458-64. Epub 2007 Jun 26.

PMID:
17595355
2.

Effects of pioglitazone on lipid and lipoprotein profiles in patients with type 2 diabetes and dyslipidaemia after treatment conversion from rosiglitazone while continuing stable statin therapy.

Berhanu P, Kipnes MS, Khan MA, Perez AT, Kupfer SF, Spanheimer RC, Demissie S, Fleck PR.

Diab Vasc Dis Res. 2006 May;3(1):39-44. Erratum in: Diab Vasc Dis Res. 2006 Sep;3(2):71.

PMID:
16784180
3.

A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia.

Goldberg RB, Kendall DM, Deeg MA, Buse JB, Zagar AJ, Pinaire JA, Tan MH, Khan MA, Perez AT, Jacober SJ; GLAI Study Investigators.

Diabetes Care. 2005 Jul;28(7):1547-54.

PMID:
15983299
4.

Systematic review of lipid lowering for primary prevention of coronary heart disease in diabetes.

Gami AS, Montori VM, Erwin PJ, Khan MA, Smith SA; Evidence in Diabetes Enquiry System (EVIDENS) Research Group.

BMJ. 2003 Mar 8;326(7388):528-9. Review. No abstract available. Erratum in: BMJ. 2005 Jan 15;330(7483):137.

Supplemental Content

Loading ...
Support Center